Detail akcie Landec Corp online

Business Summary: Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Financial Summary: BRIEF: For the 39 weeks ended 23 February 2025, Lifecore Biomedical Inc revenues increased 2% to $92.4M. Net loss applicable to common stockholders excluding extraordinary items totaled $42.3M vs. income of $16.4M. Revenues reflect Revenues, related party increase of 11% to $39.9M. Net loss reflects single segment loss increase from $11M to $22.6M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.54 to -$1.25.